Molecular signatures for liver cancer diagnosis and treatment stratification

肝癌诊断和治疗分层的分子特征

基本信息

  • 批准号:
    10702334
  • 负责人:
  • 金额:
    $ 200.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

We are using global genomic approaches to profile clinical specimens that are associated with different stages of liver diseases. We have identified a unique diagnostic signature for patients with early onset of liver cancer and have also developed a unique molecular signature based on the mRNA gene expression of metastatic primary hepatocellular carcinoma (HCC) specimens to predict prognosis and metastasis of HCC patients. We found that this molecular signature could identify those patients who were most at risk for recurrence even in patients with early stage disease. More recently, we integrated genomic and transcriptomic profiles to search for metastasis driver genes. We found that primary tumor lesions and their match distant metastasis were similar, however significant differences could be identified between primary tumors with or without accompanying metastasis. Moreover, metastasis genes were principally tumor type and organ-site-specific, further solidifying that metastatic propensity is inherent to the primary tumor. We have also developed a unique molecular prognostic signature based on mRNA gene expression of the liver microenvironment of HCC patients. We found that a predominant humoral cytokine profile occurs in the metastatic liver microenvironment and that a shift toward anti-inflammatory/immune-suppressive responses may promote HCC metastases. Interestingly, the tumor signature is principally different from that of liver microenvironment. We have recently explored whether activated hepatic stellate cells (A-HSCs) contribute directly to HCC recurrence. We identified and validated an A-HSC-specific gene expression signature among nontumor tissues of HCC patients that was associated with HCC recurrence and survival. Further studies showed that A-HSCs preferentially alter monocyte populations to induce protumorigenic and progressive features by shifting their gene expression from an inflammatory to an immune suppressive signature. These findings indicate that disruption of the interactions and signaling events between inflammatory cells and components of the microenvironment may be useful therapeutic strategies for preventing HCC relapse. We have also found that small non-coding RNAs, termed microRNAs are associated with metastasis and could significantly predict patient survival and relapse even in early stage disease, while certain microRNAs (e.g. microRNA-26) are gender-related. Patients with low microRNA-26 expression had poor survival and were better responders to interferon therapy than those with normal expression. We developed a qRT-PCR-based matrix template and scoring algorithm (MIR26-DX) to assign patients into either low or high microRNA-26 groups. Patients with low microRNA-26 levels selected by the template were those that responded favorably to interferon-alpha therapy. We have now initiated a multi-center randomized control clinical trial in China based on these findings (NCT01681446). We also found that miR-29 family members were significantly down-regulated in AFP+ tumors with significant inverse correlation of DNMT3A gene expression and an increase in DNA methylation. AFP also inhibited transcription of the miR-29a/b-1 locus via c-MYC and promotes tumor growth of AFP- HCC cells in nude mice. Thus, tumor biology differs considerably between AFP+ HCC and AFP- HCC and that AFP is a functional antagonist of miR-29, which may contribute to global epigenetic alterations and poor prognosis in HCC. We have also used integrative approaches to identify HCC driver genes. We have combined high-resolution, array-based comparative genomic hybridization and transcriptome analysis of HCC samples to identify and validate a 10-gene signature associated with chromosome 8p loss and poor outcome. Functional studies demonstrated that three gene products have tumor suppressive properties and two of these genes, SORBS3 and SH2D4A, are linked and inhibit STAT3-mediated IL-6 signaling in HCC cells. We have also integrated metabolite and mRNA profiles to define key signaling events of HCC cancer stem cells. Our analysis revealed that stearoyl CoA desaturase (SCD), a key enzyme involved in fatty acid biosynthesis, and its related metabolites were highly elevated in stem cell-like HCC and are associated with HCC survival and aggressiveness. In a comparison of global metabolic profiles between liver, breast and pancreatic cancer tissues, we found that metabolites are principally unique to each tissue and cancer type. Thus, metabolic profiling could be applied as cancer classification tools to differentiate tumors based on tissue of origin. We have also recently analyzed metabolomic and transcriptomic profiles jointly collected from breast cancer and HCC patients to explore the associations between and build predictors of the expression of metabolic enzymes and the levels of the metabolites participating in the reactions they catalyze. A wide range of metabolites can be successfully predicted from the transcriptome. We also developed an integrative subgraph mining approach, iSubgraph, to discover patterns of miRNA-gene networks to stratify HCC patients. This algorithm could detect cooperative regulation of miRNAs and genes with highly stable class predictions. Thus, our methods can integrate various omics data derived from different platforms and with different dynamic scales to better define molecular tumor subtypes. Through recent analyses of HCC, we revealed that a large number of RNA binding proteins (RBPs) are dysregulated and that RBP dysregulation is associated with poor prognosis. We further identified that oncogenic activation of a top candidate RBP, negative elongation factor E (NELFE), via somatic copy-number alterations enhanced MYC signaling and promoted HCC progression. Interestingly, NELFE induces a unique tumor transcriptome by selectively regulating MYC-associated genes. Thus, our results revealed NELFE as an oncogenic protein that may contribute to transcriptome imbalance in HCC through the regulation of MYC signaling. The incidence of cholangiocarcinoma (CCA), a bile-duct-related cancer and second most frequent primary liver cancer (PLC), is prevalent, especially in the north-east area of Thailand. We initiated the Thailand Initiative for Genomics and Expression Research in Liver Cancer (TIGER-LC) to provide a comprehensive global analysis of genomic alterations related to the primary liver cancer types in Thai liver cancer patients. Recently, we have identified common molecular subtypes with key drivers linked to similar prognosis among 199 Thai CCA and HCC patients through systems integration of genomics, transcriptomics, and metabolomics. Our results indicate that ICC and HCC, while clinically treated as separate entities, share common molecular determinants, suggesting that a unified molecular landscape of liver cancer is required to improve diagnosis and therapy. Intratumor molecular heterogeneity of hepatocellular carcinoma is partly attributed to the presence of hepatic cancer stem cells (CSCs). Different CSC populations defined by various cell surface markers may contain different oncogenic drivers, posing a challenge in defining molecularly targeted therapeutics. We combined transcriptomic and functional analyses of hepatocellular carcinoma cells at the single-cell level to assess the degree of CSC heterogeneity. We found that hepatic CSCs at the single-cell level are phenotypically, functionally, and transcriptomically heterogeneous. CSC subpopulations contain distinct molecular signatures. *TRUNCATED*

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xin Wei Wang其他文献

Xin Wei Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xin Wei Wang', 18)}}的其他基金

Roles of microbiota-mediated hepatocarcinogenesis
微生物介导的肝癌发生的作用
  • 批准号:
    10925957
  • 财政年份:
  • 资助金额:
    $ 200.12万
  • 项目类别:
Viral exposure signatures may define individuals vulnerable for COVID-19
病毒暴露特征可能会定义个体是否容易感染 COVID-19
  • 批准号:
    10702767
  • 财政年份:
  • 资助金额:
    $ 200.12万
  • 项目类别:
Molecular signatures for liver cancer diagnosis and treatment stratification
肝癌诊断和治疗分层的分子特征
  • 批准号:
    10262066
  • 财政年份:
  • 资助金额:
    $ 200.12万
  • 项目类别:
The identification of human hepatocellular carcinoma metastasis genes
人肝癌转移基因的鉴定
  • 批准号:
    10926086
  • 财政年份:
  • 资助金额:
    $ 200.12万
  • 项目类别:
Mechanism of viral hepatitis-mediated hepatocarcinogenesis
病毒性肝炎介导的肝癌发生机制
  • 批准号:
    10262018
  • 财政年份:
  • 资助金额:
    $ 200.12万
  • 项目类别:
The identification of human hepatocellular carcinoma metastasis genes
人肝癌转移基因的鉴定
  • 批准号:
    10262174
  • 财政年份:
  • 资助金额:
    $ 200.12万
  • 项目类别:
The role of cancer stem cells in liver cancer heterogeneity and subtypes
癌症干细胞在肝癌异质性和亚型中的作用
  • 批准号:
    10262173
  • 财政年份:
  • 资助金额:
    $ 200.12万
  • 项目类别:
Roles of microbiota-mediated hepatocarcinogenesis
微生物介导的肝癌发生的作用
  • 批准号:
    10702289
  • 财政年份:
  • 资助金额:
    $ 200.12万
  • 项目类别:
Identification of viral exposure signatures for early detection of liver cancer
鉴定病毒暴露特征以早期发现肝癌
  • 批准号:
    10703084
  • 财政年份:
  • 资助金额:
    $ 200.12万
  • 项目类别:
Viral exposure signatures may define individuals vulnerable for COVID-19
病毒暴露特征可能会定义个体是否容易感染 COVID-19
  • 批准号:
    10262566
  • 财政年份:
  • 资助金额:
    $ 200.12万
  • 项目类别:

相似海外基金

DMS-EPSRC: Asymptotic Analysis of Online Training Algorithms in Machine Learning: Recurrent, Graphical, and Deep Neural Networks
DMS-EPSRC:机器学习中在线训练算法的渐近分析:循环、图形和深度神经网络
  • 批准号:
    EP/Y029089/1
  • 财政年份:
    2024
  • 资助金额:
    $ 200.12万
  • 项目类别:
    Research Grant
CAREER: Blessing of Nonconvexity in Machine Learning - Landscape Analysis and Efficient Algorithms
职业:机器学习中非凸性的祝福 - 景观分析和高效算法
  • 批准号:
    2337776
  • 财政年份:
    2024
  • 资助金额:
    $ 200.12万
  • 项目类别:
    Continuing Grant
CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
  • 批准号:
    2338816
  • 财政年份:
    2024
  • 资助金额:
    $ 200.12万
  • 项目类别:
    Continuing Grant
CAREER: Structured Minimax Optimization: Theory, Algorithms, and Applications in Robust Learning
职业:结构化极小极大优化:稳健学习中的理论、算法和应用
  • 批准号:
    2338846
  • 财政年份:
    2024
  • 资助金额:
    $ 200.12万
  • 项目类别:
    Continuing Grant
CRII: SaTC: Reliable Hardware Architectures Against Side-Channel Attacks for Post-Quantum Cryptographic Algorithms
CRII:SaTC:针对后量子密码算法的侧通道攻击的可靠硬件架构
  • 批准号:
    2348261
  • 财政年份:
    2024
  • 资助金额:
    $ 200.12万
  • 项目类别:
    Standard Grant
CRII: AF: The Impact of Knowledge on the Performance of Distributed Algorithms
CRII:AF:知识对分布式算法性能的影响
  • 批准号:
    2348346
  • 财政年份:
    2024
  • 资助金额:
    $ 200.12万
  • 项目类别:
    Standard Grant
CRII: CSR: From Bloom Filters to Noise Reduction Streaming Algorithms
CRII:CSR:从布隆过滤器到降噪流算法
  • 批准号:
    2348457
  • 财政年份:
    2024
  • 资助金额:
    $ 200.12万
  • 项目类别:
    Standard Grant
EAGER: Search-Accelerated Markov Chain Monte Carlo Algorithms for Bayesian Neural Networks and Trillion-Dimensional Problems
EAGER:贝叶斯神经网络和万亿维问题的搜索加速马尔可夫链蒙特卡罗算法
  • 批准号:
    2404989
  • 财政年份:
    2024
  • 资助金额:
    $ 200.12万
  • 项目类别:
    Standard Grant
CAREER: Efficient Algorithms for Modern Computer Architecture
职业:现代计算机架构的高效算法
  • 批准号:
    2339310
  • 财政年份:
    2024
  • 资助金额:
    $ 200.12万
  • 项目类别:
    Continuing Grant
CAREER: Improving Real-world Performance of AI Biosignal Algorithms
职业:提高人工智能生物信号算法的实际性能
  • 批准号:
    2339669
  • 财政年份:
    2024
  • 资助金额:
    $ 200.12万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了